Biotech News

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics (VKTX)Viking Therapeutics2026-05-05 11:05 ESTConference / presentation

VKTX (VKTX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vktx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VKTXViking Therapeutics2026-05-12 11:05 EST

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

VKTXViking Therapeutics2026-03-26 11:05 EST

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

ALGSAligos Therapeutics2026-02-23 13:00 EST

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 11:00 EST

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

CRNXCrinetics Pharmaceuticals2026-06-02 08:55 EST

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

MNKDMannKind2026-03-09 13:05 EST

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

VANIVivani Medical2026-01-22 12:00 EST

Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026

View all latest news

Viking Therapeutics

Viking Therapeutics is a metabolic-disease biotech focused on obesity and related cardiometabolic opportunities.

Recent company news

VKTXViking Therapeutics2026-07-23 11:05 EST

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

VKTXViking Therapeutics2026-05-21 11:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

Stock data

Close: 34.87 USD
Market cap: 3.4B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States